Acta Inform Med. 2021 Mar ;29(1):59-64. PMID: 34012215
Effects of Low Level Laser Therapy (LLLT) on Serum Values of Interleukin 6 (IL-6) in Patients with Periodontitis and Type 2 Diabetes Mellitus (T2DM).
Background: In patients with T2DM, the therapeutic effects of conservative treatment are quite limited, and there is a need for additional therapeutic procedures to achieve the desired satisfactory and solid effect. Low-level laser therapy (LLLT) has an anti-inflammatory effect, and is used to heal lesions. This mechanism is realized through inhibition of lipopolysaccharides (LPS), so it can be used in the treatment of periodontal disease in patients with diabetes.Objective: The aim of this study is to assess the effect of level laser therapy (LLLT) on serum IL-6 values in patients with periodontitis and T2DM.Methods: Patients at age between 35-60 years old, with chronic periodontitis (CH) where the clinical loss of attachment (CAL) was≥4 mm therefore covering at least 50 % of affected teeth. In this study we included 80 patients, divided into two groups: 40 patients with type 2 diabetes mellitus (2TDM) treated with conservative periodontal treatment supplemented with laser therapy (LLLT), group A, and 40 patients with 2TDM, conservatively treated without LLLT. therapy i.e. group B. The laser light was applied to the gingiva in separate quadrants in 5 sessions for the next five days in a row. Blood samples were taken from all subjects at the first treatment, then in 6 weeks and 3 months after treatment, and interleukin 6 (IL-6) levels were measured. The blood samples in the test tubes remained for about 30 minutes and were then distributed in a biochemical laboratory, where they were centrifuged at 6,000 rpm for 10 minutes. The serum was separated from the test tube and transferred to the eppendorph. All serum samples were stored at -80 ° C until complete analysis and determination of IL-6, according to the standardized methodology.Results: In group A, on the first examination serum IL-6 levels varies in the interval 11.54± 1.11 pg / mL, after 6 weeks of therapy the values range between 11.26 ± 0.77 pg / mL, and after 3 months of therapy levels oscillate at intervals of 11.02 ± 0.67 pg / mL. In group B the findings are similar. At the first examination, the serum IL-6 values were 11.56 ± 0.81 pg / mL, after 6 weeks of therapy ranged from 11.59 ± 0.71 pg / mL, and after 3 months of therapy levels were recorded at intervals. 11.41 ± 0.78 pg /mL. The serum IL-6 value after 6 weeks of therapy in patients in group B for Z = -2.04 and p